Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$18.65 USD
-0.85 (-4.35%)
Updated Apr 29, 2024 03:57 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
CALT 18.65 -0.85(-4.35%)
Will CALT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CALT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CALT
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
CALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?
Other News for CALT
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Stifel Nicolaus Sticks to Its Buy Rating for Calliditas Therapeutics (CALT)
Calliditas Triumphs with TARPEYO’s Full FDA Approval
Calliditas Therapeutics' 2023 Annual Report Published
Calliditas announces NefIgArd study achieves primary, secondary endpoints